Ceritinib in ALK-rearranged non-small-cell lung cancer.

Publication Type:

Journal Article


The New England journal of medicine, Volume 370, Issue 13, p.1189-97 (2014)


2014, April 2014, Clinical Research Division


Non-small-cell lung cancer (NSCLC) harboring the anaplastic lymphoma kinase gene (ALK) rearrangement is sensitive to the ALK inhibitor crizotinib, but resistance invariably develops. Ceritinib (LDK378) is a new ALK inhibitor that has shown greater antitumor potency than crizotinib in preclinical studies.